

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

SUPPLEMENTAL ANNOUNCEMENT

MAJOR TRANSACTION – DISPOSAL OF APPROXIMATELY 8.11% OF THE ISSUED SHARE CAPITAL OF THE TARGET COMPANY

References are made to (i) the announcement of New Ray Medicine International Holding Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 20 April 2021 in relation to the disposal of approximately 8.11% of the issued share capital of WinHealth International Company Limited (維健國際有限公司) (“**Target Company**”) by the Group; and (ii) the announcement of the Company dated 30 July 2021 in relation to, among other matters, the change of the Long Stop Date. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the aforesaid announcements (collectively, the “**Announcements**”).

The Company has been recently informed by the Target Company that subsequent to the signing of the Share Repurchase Agreement on 20 April 2021, the Target Company allotted and issued new shares to one of its existing shareholders. Based on the representations of the Target Company, immediately after the allotment and issue of the new shares, the shareholding of the Vendor (a wholly-owned subsidiary of the Company) in the Target Company was diluted from approximately 8.11% to approximately 7.87%. The Consideration payable by the Purchaser to the Vendor for the Disposal remains unchanged.

As at the date of this announcement, the Group is beneficially interested in approximately 7.87% of the issued share capital of the Target Company.

Save as disclosed above, all material terms of the Share Repurchase Agreement as disclosed in the Announcements remain unchanged.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 5 August 2021

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.

Note: Trading in the Shares has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the Securities and Futures Commission in accordance with its direction issued under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V, the Laws of Hong Kong). Trading in the Shares will remain suspended until further notice. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.